DDInter1765 DDInter1658
Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Teniposide {u} (Compound) resembles {v} (Compound) Podofilox
Teniposide {u} (Compound) treats {v} (Disease) lung cancer
Teniposide {u} (Compound) binds {v} (Gene) CYP2C9
Teniposide {u} (Compound) upregulates {v} (Gene) EDEM1
Teniposide {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Teniposide {u} (Compound) downregulates {v} (Gene) CLTC
Teniposide {u} (Compound) causes {v} (Side Effect) Flushing
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Teniposide (Compound) resembles Podofilox (Compound)
Teniposide (Compound) treats lung cancer (Disease)
Teniposide (Compound) binds CYP2C9 (Gene)
Teniposide (Compound) upregulates EDEM1 (Gene)
Teniposide (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Teniposide (Compound) downregulates CLTC (Gene)
Teniposide (Compound) causes Flushing (Side Effect)
Teniposide may cause a minor interaction that can limit clinical effects when taken with Delavirdine
Teniposide may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa